NCT02015273

Brief Summary

This is an Multinational, Multicenter, Observational Study to evaluate Adherence and Long Term Outcomes of Therapy in pediatric subjects using easypod™ electromechanical device for growth hormone treatment and to assess the level of adherence of subject receiving SAIZEN® via easypod™.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
82

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2014

Geographic Reach
3 countries

6 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 18, 2013

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 19, 2013

Completed
2 months until next milestone

Study Start

First participant enrolled

February 28, 2014

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2015

Completed
Last Updated

July 7, 2020

Status Verified

July 1, 2020

Enrollment Period

1.8 years

First QC Date

December 18, 2013

Last Update Submit

July 3, 2020

Conditions

Growth Disorders

Keywords

easypod™SAIZEN®

Outcome Measures

Primary Outcomes (1)

  • Mean percent of daily recorded adherence

    At least 6 months and up to 2.5 years

Secondary Outcomes (3)

  • Correlation of adherence and growth outcome after each year of SAIZEN® treatment with easypod™

    At least 6 months and up to 2.5 years

  • Subject adherence profile based on age, gender, indication, self-injection or not, time on treatment

    At least 6 months and up to 2.5 years

  • Correlation of adherence with current IGF-1 status (that is, above, below or within normal ranges)

    At least 6 months and up to 2.5 years

Study Arms (1)

Growth Disorders

Device: easypod™

Interventions

easypod™DEVICE

Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™

Also known as: Somatropin
Growth Disorders

Eligibility Criteria

Age2 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Pediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using the easypod™ electromechanical device.

You may qualify if:

  • Administered growth hormone via the easypod™ electromechanical device according to Summary of Product Characteristic (SmPC)
  • Over the age of 2 years
  • Under 18 years of age, or over 18 without fusion of growth plates
  • Parent's or guardian's written informed consent, given before entering data into the observational study, with the understanding that the subject or parent/guardian may withdraw consent at any time without prejudice to future medical care. If the child is old enough to read and write, a separate assent form will be given as defined in the appropriate jurisdiction of each country

You may not qualify if:

  • Subjects taking growth hormone in whom growth plates have fused (that is, for taking growth hormone for it's metabolic effects)
  • Contra-indications to SAIZEN® as defined in the SmPC
  • Use of an investigational drug or participation in another interventional clinical study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

Anakku Clinic Pondok Pinang

Jakarta, Indonesia

Location

KK Women's & Children's Hospital

Singapore, Singapore

Location

National University Hospital

Singapore, Singapore

Location

Kaohsiung Medical University Hospital

Kaohsiung City, Taiwan

Location

Chung Shan Medical University Hospital

Taichung, Taiwan

Location

Taipei Medical University Hospital

Taipei, Taiwan

Location

Related Publications (2)

  • Koledova, E. et al. (2017) Analysis of results from the global, 5-year Easypod™ Connect Observational Study (ECOS) study in children with growth disorders. 10th International Meeting for Pediatric Endocrinology; 2017 Sep 14-17; Washington, DC.

    RESULT

  • Wit, JM. et al. (2017) Effect of adherence on the 2-year growth response to growth hormone treatment in prepubertal children with idiopathic isolated growth hormone deficiency participating in the EasypodTM Connect Observational Study (ECOS). 10th International Meeting of Paediatric Endocrinology; 2017 Sep 14-17; Washington, DC.

    RESULT

Related Links

MeSH Terms

Conditions

Growth Disorders

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Medical Responsible

    Merck Ltd., Taiwan

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 18, 2013

First Posted

December 19, 2013

Study Start

February 28, 2014

Primary Completion

December 31, 2015

Study Completion

December 31, 2015

Last Updated

July 7, 2020

Record last verified: 2020-07

Locations

SG(2)TW(3)ID(1)